On December 7 Roche announced the FDA approval of its triplet of programmed...
- Poxel closes enrolment in TIMES 2 trial of Imeglimin in Japan
- Cocrystal Pharma to study hepatitis C drug in Hong Kong
- Allergan assesses brazikumab in two clinical programmes for IBD
- Cardax doses first patient in CHASE trial for cardiovascular health drug
- Oxurion enrols first patient in Phase l trial of THR-687 for DME
Vedanta Biosciences starts Phase II VE303 trial to treat rCDI
Vedanta Biosciences has commenced a Phase II trial to investigate the safety and efficacy of VE303 in comparison with placebo for the treatment of patients with recurrent clostridium difficile infection (rCDI).
Lilly reports positive top-line results from SPIRIT-H2H study for PsA
Eli Lilly and Company (Lilly) has reported positive top-line results from the Phase IIIb/IV SPIRIT-H2H study of Taltz in comparison with humira (adalimumab) to treat patients with active psoriatic arthritis (PsA) who are biologic disease-modifying anti-rheumatic drug (DMARD)-naive.
Roche’s Tecentriq triplet versus Keytruda + chemotherapy: an Uphill Struggle?
On December 7 Roche announced the FDA approval of its triplet of programmed death-ligand 1 (PD-L1) inhibitor Tecentriq (atezolizumab) + vascular endothelial growth factor (VEGF) inhibitor Avastin (bevacizumab) + chemotherapy (paclitaxel + carboplatin) in the highly prized indication of untreated non-squamous non-small cell lung cancer (NSCLC).
Quick and Flexible Elemental Screening with Omnian
Omnian was developed for Malvern Panalytical's high-end x-ray fluorescence (XRD) spectrometer and is also available for the Epsilon 4 energy dispersive x-ray fluorescence (EDXRF) benchtop systems. This powerful combination brings together the strengths of Omnian with the ease-of-use of Epsilon 4.
Valneva starts Phase ll trial of VLA15 to treat Lyme disease
Valneva has commenced a Phase ll VLA15-201 clinical trial of VLA15 vaccine for the treatment of Lyme disease, a systemic infection caused by Borrelia burgdorferi bacteria.
Rhythm enrols first patient in Phase lll trial of setmelanotide
Rhythm Pharmaceuticals has enrolled the first patient in a pivotal Phase lll clinical trial examining setmelanotide for the treatment of patients with Bardet-Biedl Syndrome (BBS) and Alström Syndrome.
Sensorion reports positive topline data from SENS-111-202 study
Sensorion has reported positive topline results from the SENS-111-202 study after the trial met its primary endpoint of tolerability.
Innovent reports positive results from two trials of IBI305
Innovent Biologics has reported positive results from two clinical trials of IBI305 after meeting the pre-defined primary endpoints of both studies.
Janssen reports positive results from plaque psoriasis trial
Janssen Pharmaceutical Companies of Johnson & Johnson has reported positive results from the Phase III ECLIPSE trial that investigated the efficacy and safety of tremfya (guselkumab) in comparison with cosentyx (secukinumab) in adult patients with moderate to severe plaque psoriasis.
Aptevo doses first patient in Phase l/lb trial of APVO436
Aptevo Therapeutics has dosed the first patient in a Phase l/lb clinical trial of APVO436 for the treatment of patients with acute myeloid leukaemia (AML) and high-grade myelodysplastic syndrome (MDS).
Read our magazine
Pharma Technology Focus is the essential reading material for decision-makers in the pharmaceutical industry, bringing you the latest news and analysis in an exciting, interactive format.